Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial.

Cancer · 2017 · PMC5516140 · PMID 28339098

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantP < .001actually significant

At 12 months, the difference between groups was highly significant ( P < .001), diarrhea being reported more by patients in group C than those in group A or B.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.